Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366
This study is recruiting at 37 US sites in 20 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- High Grade Epithelial Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
- Mesothelioma
- Breast Adenocarcinoma
- Triple Negative Breast Cancer
- Hormone Receptor-positive/Her2 Negative Breast Cancer
- Platinum-resistant Ovarian Cancer (PROC)
- Platinum Sensitive Ovarian Cancer (PSOC)
- Primary Refractory Ovarian Cancer
- Uterine Cancer
- Cervical Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Genmab
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- USOR HonorHealth · Phoenix, AZ
- USOR Arizona Oncology Associates · Tucson, AZ
California · 4
- University of California Los Angeles Medical Center · Los Angeles, CA
- University of California, San Diego; Moores Cancer Center · San Diego, CA
- USOR Sansum Clinic · Santa Barbara, CA
- Providence Medical Foundation · Santa Rosa, CA
Florida · 3
- USOR Florida Cancer Specialists South · Fort Myers, FL
- USOR Florida Cancer Specialists North · St. Petersburg, FL
- USOR Florida Cancer Specialists East · West Palm Beach, FL
Georgia · 1
- Augusta University Georgia Cancer Center · Augusta, GA
Kansas · 1
- University of Kansas Medical Center (KUMC) · Westwood, KS
Maryland · 1
- USOR Maryland Oncology Hematology · Rockville, MD
Massachusetts · 2
- Dana Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Michigan · 2
- Karmanos Cancer Institute · Detroit, MI
- START Midwest · Grand Rapids, MI
Minnesota · 1
- USOR Minnesota Oncology Hematology · Maplewood, MN
New Jersey · 1
- MD Anderson Cancer Center at Cooper- Two Cooper Plaza · Camden, NJ
Ohio · 1
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute · Columbus, OH
Oklahoma · 1
- University of Oklahoma - Health Sciences Center · Oklahoma City, OK
Oregon · 2
- USOR Oncology Associates of Oregon, P.C. · Eugene, OR
- Compass Oncology - Rose Quarter · Portland, OR
Pennsylvania · 2
- USOR Alliance Cancer Specialist · Doylestown, PA
- Allegheny Health Network · Pittsburgh, PA
Rhode Island · 1
- Women and Infants Hospital of Rhode Island · Providence, RI
Tennessee · 2
- Sarah Cannon Research Institute at Tennessee Oncology · Nashville, TN
- Tennessee Oncology · Nashville, TN
Texas · 6
- USOR Texas Oncology · Abilene, TX
- Texas Oncology - Central / South Texas · Austin, TX
- Mary Crowley Cancer Research · Dallas, TX
- USOR Texas Oncology · Fort Worth, TX
- Texas Oncology - Northeast TX · Tyler, TX
- USOR Texas Oncology Gulf Coast · Woodland, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Virginia · 2
- USOR Virginia Cancer Specialists · Fairfax, VA
- USOR Virginia Oncology Associates · Norfolk, VA
Washington · 1
- Swedish Cancer Institute · Everett, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.